Burcon Nutrascience Achieves Key Commercial Milestones with Plant Protein Production and Secures Growth Financing
Burcon Nutrascience Corporation advances commercialization of its plant proteins with first commercial production and sales, while securing $4 million in financing to support growth toward profitability.
Stonegate Capital Partners has updated coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting significant commercial progress in the plant protein sector. During the second quarter of fiscal year 2026, Burcon achieved first commercial production and sales of Puratein® C canola protein and first commercial production of FavaPro™ fava protein at its Galesburg facility, while continuing to scale Peazazz® C pea protein operations. These developments mark critical milestones in the company's transition from development to commercial operations.
The company's operational execution demonstrates growing market traction, with more than 200 active projects progressing through late-stage evaluations across diverse end-market applications in food, beverage, and lifestyle nutrition. Subsequent to quarter-end, Burcon received over $500,000 in commercial sales orders and recorded the first commercial sale of FavaPro, indicating that customer evaluations are converting to purchase decisions. This operational flexibility positions the company to respond quickly to evolving customer demands while maintaining consistent product quality.
Financial performance showed substantial improvement, with second quarter revenues reaching $0.36 million, representing a 783% increase over the same period last year. Year-to-date revenue totaled approximately $0.7 million, driven by initial protein sales and contract manufacturing activities. The company's net loss for the quarter was $3.59 million, or $0.28 per share, which included $2.1 million in cost of goods sold that encompassed startup and commissioning costs. Operating expenses showed positive trends, with research and development costs decreasing 67% and general and administrative expenses down 17% from the prior year period, reflecting the company's shift toward commercialization focus.
To support continued growth, Burcon announced a non-brokered private placement of up to $4.0 million in unsecured convertible debentures bearing 15% annual interest with a 48-month term. The financing includes a conversion price of $2.27 per share and features a conditional accelerated prepayment or conversion feature if the share price trades above $4.54 for 14 consecutive trading days. Company insiders committed to a minimum of $2.0 million of the offering. Additionally, the company executed a $700,000 short-term unsecured loan with an entity related to a director at 12% interest to bridge to the debenture closing and extended the maturity of the second tranche of its senior secured loan to December 2026.
Proceeds from these financing activities are intended for inventory buildup, labor expansion, production capability enhancements, future infrastructure planning, general corporate purposes, and repayment of the bridge loan. The company ended the quarter with $1.8 million in cash and a working capital deficit of $8.2 million, though subsequent financing actions and order receipts have strengthened the company's financial position. Management reaffirmed its calendar year 2025 revenue target of $1-3 million and maintained its calendar year 2026 outlook for $10 million plus revenue with a path to positive cash flow. Stonegate Capital Partners' valuation analysis using discounted cash flow modeling suggests a valuation range of $20.29 to $25.66 with a midpoint of $22.61, based on discount rates between 10.50% and 11.00%.